Lupus Pernio

17
GRAND ROUNDS USC DERMATOLOGY MAY 3, 2011 JENNIFER ARMSTRONG Lupus Pernio

description

Lupus Pernio presented by Jennifer Armstrong Grand Rounds, USC Dermatology May 3, 2011

Transcript of Lupus Pernio

Page 1: Lupus Pernio

GRAND ROUNDSUSC DERMATOLOGY

MAY 3 , 2011

JENNIFER ARMSTRONG

Lupus Pernio

Page 2: Lupus Pernio

Overview

Sarcoidosis is a multisystem granulomatous inflammatory disease that can affect any organ.

Cutaneous lesions present in 20%-35% of patients

Page 3: Lupus Pernio

Lupus Pernio

Lupus pernio, first described by Besnier in 1889, is a manifestation of sarcoidal skin lesions.

Page 4: Lupus Pernio

Lupus Pernio

Its name comes from Latin perniō = chilblain on the foot.

Inflammation of the skin of the hands or feet, resulting from exposure to cold

Thought to resemble a mild frostbite

Lupus Pernio

Frostbite

Page 5: Lupus Pernio

Epidemiology

More common in African American’s and Puerto Rican populations

Female> MaleUsually with long-

standing systemic, usually pulmonary disease

Page 6: Lupus Pernio

Etiology

The etiology of this disease is still unknown.

The serum concentration of angiotensin-converting enzyme (ACE) is increased, and measurements have been used as an index of disease activity.

Page 7: Lupus Pernio

Cutaneous Findings: violaceous, indurated plaques and nodules

………………………………………………………Ears

…..…………………………………………………………………….Nose

………………………… Dorsum of hand, fingers

……………………………….………… Toes

…………………………………Cheeks and Lips

Page 8: Lupus Pernio

Organs Involved

………………..…………Chronic Uveitis/Occular lesions 37%

…….……..….. Intrathoracic Involvement in 74%

………………………………..Bone Cysts 43%

Page 9: Lupus Pernio

Key Findings

Cutaneous involvement is either specific or nonspecific.

Specific lesions manifest as noncaseating granulomas that consist of mononuclear

phagocytes, epithelioid macrophages and multinucleate giant cells

Whereas nonspecific lesions (EN) do not reveal granulomas on histopathologic examination.

Page 10: Lupus Pernio

Standard Treatment

A stepwise approach to patient care is appropriate

First Line: mild skin-limited disease. Potent topical corticosteroids

clobetasol Intralesional injections

triamcinolone (3-10 mg/mL)

First Line: deforming skin lesions or for widespread disease Systemic therapy: prednisone 40-80 mg/day tapered

used alone or in combination with antimalarials or methotrexate

Page 11: Lupus Pernio

Standard Treatment

Second Line Antimalarials and methotrexate may be used as

monotherapy for steroid-resistant sarcoidosis or in patients unable to tolerate steroids. Given the concern regarding ocular toxicity, the

maximum dosages of chloroquine and hydroxychloroquine should not exceed 3.5 and 6.5 mg/kg/day, respectively.

Methotrexate is given in weekly doses of 10-30 mg

Page 12: Lupus Pernio

Treatment – Chronic/Refractory

TNF-α antagonists Infliximab ( IV 3-10 mg/kg at 0, 2 and 6 weeks) Etanercept (injected subcutaneously at doses of 40

mg either weekly or every 2 weeks) Thalidomide may have a role in cutaneous sarcoidosis,

especially in refractory and chronic cases that are resistant to the standard regimens. 50 to >400 mg/day (average 100mg/day) has limited, but

promising supporting data

Page 13: Lupus Pernio

Other

Isotretinoin, 0.5-2 mg/kg/day, has been used successfully in a handful of reported cases.

Ablative: Pulsed dye or CO2 laser is available for the debulking of granulomatous lesions However, there are no evidence-based

recommendations because of the limited number of patients treated

Melatonin (20 mg/day) and allopurinol (100-300 mg/day) are not well studied in cutaneous sarcoidosis, and the clinical experience with tetracycline derivatives has been mixed.

Page 14: Lupus Pernio

Prognosis

The course is usually chronic, and severe cosmetic disfigurement may result.

Lupus pernio, especially involving the nasal rim, has pulmonary involvement upper respiratory tract

(50%) lungs (75%).

Page 15: Lupus Pernio

Differential Diagnosis

•Lupus vulgaris•Deep Fungal•Lupus erythematosus•Rhinophyma when localized to the nose•Malignant pleomorphic lymphoma•Protracted superficial Wegener's granulomatosis•Tertiary syphilis

•Discoid Lupus

Page 16: Lupus Pernio

References

• Chensue SW, Warmington K, Ruth J, Lincoln P, Kuo MC, Kunkel SL: Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor.Am J Path 1994, 145:1105-1113

• Badgwell C, Rosen T: Cutaneous sarcoidosis therapy updated.J Am Acad Dermatol 2007, 56:69-83

• Shakoory B, Chathman W. Recognizing and managing the musculoskeletal manifestations of Sarcoidosis. The Journal of Musculoskeletal Medicine 2008, 25: 12 

• Baughman RP, Lower EE. Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol. 2004;5(6):385-94.

• Yayoi NAGAI, Naoya IGARASHI, Osamu ISHIKAWA. Lupus pernio with multiple bone cysts in the fingers. The Journal of Dermatology Volume 37, Issue 9, pages 812–814, September 201

Page 17: Lupus Pernio

References cont.

James DG. Lupus pernio. Lupus. 1992 May;1(3):129-31

Fernandez-Faith E, McDonnell Cutaneous sarcoidosis: differential diagnosis. J.Clin Dermatol. 2007 May-Jun;25(3):276-87.

Takashi Koyama, MD, Hiroyuki Ueda, MD, Kaori Togashi, MD, Shigeaki Umeoka, MD, Masako Kataoka, MD and Sonoko Nagai, MD. Radiologic Manifestations of Sarcoidosis in Various Organs. RadioGraphics. March-April 2011, 31 (2)

Marchell, Richard M; Judson, Marc. A Cutaneous Sarcoidosis Semin Respir Crit Care Med 2010; 31: 442-451

Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68(10):1361-83.

PICS: TheAltitudeExperience.com, Dermis.net, dermatlas, Journal of Head and Neck Medicine, Lexic, emedicine, Access Medicine